Maribavir isomers, compositions, methods of making and methods of using
The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
1 . A method of treating a cytomegalovirus (CMV) infection in a patient having a CMV infection, the method comprising orally administering to the patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole in an amount of 400 mg twice a day, wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium, wherein said composition is an immediate release formulation, and wherein the immediate release formulation releases said compound from said formulation by dissolution in less than 60 minutes.
2 . A method of treating a cytomegalovirus (CMV) infection in a patient having a CMV infection, the method comprising orally administering to the patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole in an amount of 400 mg twice a day, wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium, wherein said composition is an immediate release formulation, and wherein the immediate release formulation releases said compound from said formulation in vivo in less than 60 minutes following administration.